For The Better

Coinbase is still a cut above the rest.

Which of these top-performing growth funds is the better buy?

One thing is for certain — both of these companies are innovators.

Despite soaring nearly 50% this year, this tech stock might be worth holding onto.

Advanced Micro Devices compares its MI300X to Nvidia’s H100.

Eli Lilly’s P/E ratio of more than 100 looks steep, but the company is on the cusp of further huge growth.

High earners can go the backdoor Roth IRA route to take advantage of the account’s benefits.

Anyone can adopt this effective strategy.

Can ChargePoint really achieve positive adjusted EBITDA in the next 12 months?

Exscientia has the potential to be a star collaborator and a profitable drug developer, too.

One of Palantir’s largest contracts is coming up for renewal.

PepsiCo’s snack division is spurring growth for the food and beverage giant.

All cheap valuations are not the same.

Can this high-flying AI stock continue its terrific surge in 2024?

That raise you’ve been waiting for is almost here.

Exxon is once again increasing its investments in lower-carbon energy.

Medicare Advantage plans are growing increasingly popular. But these plans come with several drawbacks that enrollees should know about.

Are hopes of a turnaround too farfetched for this beaten-down cannabis stock?

Palantir has had an incredible 2023, but it has a big hill to climb in 2024.

In coordination with Bitcoin Park, ARK is pleased to introduce a monthly conversation with leaders in the Bitcoin space.